The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Open accessAbstract
Inhibiting glycogen synthase kinase-3 (GSK-3) activity via pharmacological intervention has become an important strategy for treating neurodegenerative and psychiatric disorders. The known GSK-3 inhibitors are of diverse chemotypes and mechanisms of action and include compounds isolated from natural sources, cations, synthetic small-molecule ATP-competitive inhibitors, non-ATP-competitive inhibitors, and substrate-competitive inhibitors. Here we describe the variety of GSK-3 inhibitors with a specific emphasis on their biological activities in neurons and neurological disorders. We further highlight our current progress in the development of non-ATP-competitive inhibitors of GSK-3. The available data raise the hope that one or more of these drug design approaches will prove successful at stabilizing or even reversing the aberrant neuropathology and cognitive deficits of certain central nervous system disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, G., Bower, K. A., Ma, C., Fang, S., Thiele, C. J., & Luo, J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1551fje · Cited by 310
RetractedThe ground state of embryonic stem cell self-renewal
Ying, Q.-L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P., & Smith, A. (2008) · Nature · doi:10.1038/nature06968 · Cited by 3,442
Specificity and mechanism of action of some commonly used protein kinase inhibitors
DAVIES, S. P., REDDY, H., CAIVANO, M., & COHEN, P. (2000) · Biochemical Journal · doi:10.1042/bj3510095 · Cited by 3,132
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Hanks, S. K., & Hunter, T. R. (1995) · PubMed · Cited by 2,518
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130
Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., & Brivanlou, A. H. (2004) · Nature Medicine · doi:10.1038/nm979 · Cited by 2,109
GSK-3: tricks of the trade for a multi-tasking kinase
Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084
GSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation
Hoeflich, K. P., Luo, J., Rubie, E. A., Tsao, M.-S., Jin, O., & Woodgett, J. R. (2000) · Nature · doi:10.1038/35017574 · Cited by 1,393
The specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 3×
“Systemic analysis that profiled protein kinase inhibitors also confirmed the high selectivity of CHIRs toward GSK-3 (Bain et al., 2003, 2007).”
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Ikeda, S. (1998) · The EMBO Journal · doi:10.1093/emboj/17.5.1371 · Cited by 1,246
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191
Lucas, J. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 900
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
GSK-3β Regulates Phosphorylation of CRMP-2 and Neuronal Polarity
Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A., & Kaibuchi, K. (2005) · Cell · doi:10.1016/j.cell.2004.11.012 · Cited by 875
GSK3: a multifaceted kinase in Wnt signaling
Wu, D., & Pan, W. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.10.002 · Cited by 857
GSK3 signalling in neural development
Hur, E.-M., & Zhou, F.-Q. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2870 · Cited by 838
Hoessel, R., Leclerc, S., Endicott, J. A., Nobel, M. E. M., Lawrie, A., Tunnah, P., Leost, M., Damiens, E., Marie, D., Marko, D., et al. (1999) · Nature Cell Biology · doi:10.1038/9035 · Cited by 809
GSK-3-Selective Inhibitors Derived from Tyrian Purple Indirubins
Meijer, L., Skaltsounis, A.-L., Magiatis, P., Polychronopoulos, P., Knockaert, M., Leost, M., Ryan, X. P., Vonica, C. A., Brivanlou, A., Dajani, R., et al. (2003) · Chemistry & Biology · doi:10.1016/j.chembiol.2003.11.010 · Cited by 808
Beaulieu, J.-M., Sotnikova, T. D., Yao, W.-D., Kockeritz, L., Woodgett, J. R., Gainetdinov, R. R., & Caron, M. G. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307921101 · Cited by 793
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Mao, Y., Ge, X., Frank, C. L., Madison, J. M., Koehler, A. N., Doud, M. K., Tassa, C., Berry, E. M., Soda, T., Singh, K. K., et al. (2009) · Cell · doi:10.1016/j.cell.2008.12.044 · Cited by 774
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Crystal Structure of Glycogen Synthase Kinase 3β
Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., & Pearl, L. H. (2001) · Cell · doi:10.1016/s0092-8674(01)00374-9 · Cited by 674
Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation.
Hughes, K., Nikolakaki, E., Plyte, S. E., Totty, N. F., & Woodgett, J. R. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05715.x · Cited by 629
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Ring, D. B., Johnson, K. W., Henriksen, E. J., Nuss, J. M., Goff, D., Kinnick, T. R., Ma, S. T., Reeder, J. W., Samuels, I., Slabiak, T., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.3.588 · Cited by 532
Both the Establishment and the Maintenance of Neuronal Polarity Require Active Mechanisms
Jiang, H., Guo, W., Liang, X., & Rao, Y. (2005) · Cell · doi:10.1016/j.cell.2004.12.033 · Cited by 494
Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium
Ryves, W. J., & Harwood, A. J. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4169 · Cited by 493
Phosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation
Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., et al. (2008) · Science · doi:10.1126/science.1156037 · Cited by 484
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · cited 1×
“Although their mechanism of action has not yet been experimentally confirmed, a possible role has been postulated for an interaction with cysteine 199, a key residue located in the active site of GSK-3 (Mazanetz and Fischer, 2007).”
Martinez, A., Alonso, M., Castro, A., Pérez, C., & Moreno, F. J. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011020u · Cited by 455
Self-citationMeijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
Glycogen Synthase Kinase-3β: A Novel Regulator of Cardiac Hypertrophy and Development
Hardt, S. E., & Sadoshima, J. (2002) · Circulation Research · doi:10.1161/01.res.0000018952.70505.f1 · Cited by 438
Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435
Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium
De Sarno, P., Li, X., & Jope, R. S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00215-0 · Cited by 434
O'Brien, W. T., Harper, A. D., Jové, F., Woodgett, J. R., Maretto, S., Piccolo, S., & Klein, P. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4753-03.2004 · Cited by 415
Structure of GSK3beta reveals a primed phosphorylation mechanism.
ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H.-M., Swenson, L. L., & Jain, J. (2001) · Nature Structural Biology · doi:10.1038/89624 · Cited by 407
Glycogen synthase kinase 3: an emerging therapeutic target
Eldar-Finkelman, H. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02266-3 · Cited by 407
Self-citationGSK-3 is a master regulator of neural progenitor homeostasis
Kim, W.-Y., Wang, X., Wu, Y., Doble, B. W., Patel, S., Woodgett, J. R., & Snider, W. D. (2009) · Nature Neuroscience · doi:10.1038/nn.2408 · Cited by 399
Polychronopoulos, P., Magiatis, P., Skaltsounis, A.-L., Myrianthopoulos, V., Mikros, E., Tarricone, A., Musacchio, A., Roe, S. M., Pearl, L., Leost, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm031016d · Cited by 380
Cross, D. A. E., Culbert, A. A., Chalmers, K. A., Facci, L., Skaper, S. D., & Reith, A. D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00251.x · Cited by 377
Synthetic small molecules that control stem cell fate
Ding, S., Wu, T. Y. H., Brinker, A., Peters, E. C., Hur, W., Gray, N. S., & Schultz, P. G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0732087100 · Cited by 376
Paullones are potent inhibitors of glycogen synthase kinase‐3β and cyclin‐dependent kinase 5/p25
Leost, M., Schultz, C., Link, A., Wu, Y., Biernat, J., Mandelkow, E., Bibb, J. A., Snyder, G. L., Greengard, P., Zaharevitz, D. W., et al. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01673.x · Cited by 376
Li, W., Sun, W., Zhang, Y., Wei, W., Ambasudhan, R., Xia, P., Talantova, M., Lin, T., Kim, J., Wang, X., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014041108 · Cited by 375
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder
Nunes, P. V., Forlenza, O. V., & Gattaz, W. F. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.029868 · Cited by 368
Role of GSK3β in behavioral abnormalities induced by serotonin deficiency
Beaulieu, J.-M., Zhang, X., Rodriguiz, R. M., Sotnikova, T. D., Cools, M. J., Wetsel, W. C., Gainetdinov, R. R., & Caron, M. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711496105 · Cited by 368
A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo
Serenó, L., Coma, M., Rodríguez, M., Sánchez-Ferrer, P., Sánchez, M. B., Gich, I., Agulló, J. M., Pérez, M., Avila, J., Guardia-Laguarta, C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.025 · Cited by 368
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358
Nutrition and Depression: Implications for Improving Mental Health Among Childbearing-Aged Women
Bodnar, L. M., & Wisner, K. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.009 · Cited by 351
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
Schultz, C., Link, A., Leost, M., Zaharevitz, D. W., Gussio, R., Sausville, E. A., Meijer, L., & Kunick, C. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm9900570 · Cited by 334
De Ferrari, G. V., Chacón, M. A., Barría, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., Reyes, A. E., Alvarez, A., Bronfman, M., & Inestrosa, N. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001208 · Cited by 332
Alternative routes of insulin delivery
Owens, D. R., Zinman, B., & Bolli, G. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01076.x · Cited by 332
GBP, an Inhibitor of GSK-3, Is Implicated in Xenopus Development and Oncogenesis
Yost, C., Farr, G. H., Pierce, S. B., Ferkey, D. M., Chen, M. M., & Kimelman, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81208-8 · Cited by 328
COLE, A., FRAME, S., & COHEN, P. (2004) · Biochemical Journal · doi:10.1042/bj20031259 · Cited by 324
Gould, T. D., Einat, H., Bhat, R., & Manji, H. K. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004535 · Cited by 314
Hampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Glycogen Synthase Kinase-3β Facilitates Staurosporine- and Heat Shock-induced Apoptosis
Bijur, G. N., De Sarno, P., & Jope, R. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7583 · Cited by 301
Amyloid Activates GSK-3β to Aggravate Neuronal Tauopathy in Bigenic Mice
Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., & Van Leuven, F. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.070904 · Cited by 300
Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-on, P., Rose, J. B., Crews, L., & Masliah, E. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4321-06.2007 · Cited by 288
A Chaperone-Dependent GSK3β Transitional Intermediate Mediates Activation-Loop Autophosphorylation
Lochhead, P. A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N., & Cleghon, V. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.10.009 · Cited by 283
Fiol, C. J., Williams, J. S., Chou, C. H., Wang, Q. M., Roach, P. J., & Andrisani, O. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31619-3 · Cited by 277
Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., & Eldar-Finkelman, H. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.008 · Cited by 276
Self-citationThe role of GSK‐3 in synaptic plasticity
Peineau, S., Bradley, C., Taghibiglou, C., Doherty, A., Bortolotto, Z. A., Wang, Y. T., & Collingridge, G. L. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.2 · Cited by 263
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Shi, S.-H., Cheng, T., Jan, L. Y., & Jan, Y.-N. (2004) · Current Biology · doi:10.1016/j.cub.2004.11.009 · Cited by 259
Cdk5 deregulation in the pathogenesis of Alzheimer's disease
Cruz, J. C., & Tsai, L.-H. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.07.001 · Cited by 258
Kim, W.-Y., Zhou, F.-Q., Zhou, J., Yokota, Y., Wang, Y.-M., Yoshimura, T., Kaibuchi, K., Woodgett, J. R., Anton, E. S., & Snider, W. D. (2006) · Neuron · doi:10.1016/j.neuron.2006.10.031 · Cited by 235
Thomas, G. M., Frame, S., Goedert, M., Nathke, I., Polakis, P., & Cohen, P. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01161-8 · Cited by 229
Polter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C. A., Sweatt, J. D., McMahon, L., Bartolucci, A. A., Li, X., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.43 · Cited by 225 · cited 1×
“…implicate GSK-3 activity in mood behavior and indicate that elevated GSK-3 activity is associated with manic and depressive behavior (Gould et al., 2004a; Kaidanovich-Beilin et al., 2004; O’Brien et al., 2004; Prickaerts et al., 2006; Beaulieu et al., 2008; Mines et al., 2010; Polter et al., 2010).”
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
Caccamo, A., Oddo, S., Tran, L. X., & LaFerla, F. M. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061178 · Cited by 217
Multisite phosphorylation of glycogen synthase
Woodgett, J. R., & Cohen, P. (1984) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(84)90047-5 · Cited by 211
Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E., & Jope, R. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009706 · Cited by 208
Karege, F., Perroud, N., Burkhardt, S., Schwald, M., Ballmann, E., La Harpe, R., & Malafosse, A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.036 · Cited by 208
Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3β
Mukai, F., Ishiguro, K., Sano, Y., & Fujita, S. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00918.x · Cited by 204
Gompel, M., Leost, M., De Kier Joffe, E. B., Puricelli, L., Franco, L. H., Palermo, J., & Meijer, L. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.01.050 · Cited by 204
The effects of lithium on cognition: an updated review
Pachet, A. K., & Wisniewski, A. M. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1592-x · Cited by 203
Glycogen synthase kinase-3β is highly activated in nuclei and mitochondria
Bijur, G. N., & Jope, R. S. (2003) · NeuroReport · doi:10.1097/00001756-200312190-00025 · Cited by 203
Carmichael, J., Sugars, K. L., Bao, Y. P., & Rubinsztein, D. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204861200 · Cited by 195
Zhao, Y., Altman, B. J., Coloff, J. L., Herman, C. E., Jacobs, S. R., Wieman, H. L., Wofford, J. A., Dimascio, L. N., Ilkayeva, O., Kelekar, A., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00153-07 · Cited by 193
Schizophrenia as a GSK-3 dysregulation disorder
Lovestone, S., Killick, R., Di Forti, M., & Murray, R. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.02.002 · Cited by 192
Taylor, S. S., Radzio‐Andzelm, E., & Hunter, T. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.13.7557015 · Cited by 188
Crowder, R. J., & Freeman, R. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006160200 · Cited by 181
1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3β
Kunick, C., Lauenroth, K., Leost, M., Meijer, L., & Lemcke, T. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.10.062 · Cited by 179
Validating GSK3 as an in vivo target of lithium action
O'Brien, W. T., & Klein, P. S. (2009) · Biochemical Society Transactions · doi:10.1042/bst0371133 · Cited by 177
Abnormalities in brain structure and behavior in GSK-3alpha mutant mice
Kaidanovich-Beilin, O., Lipina, T. V., Takao, K., van Eede, M., Hattori, S., Laliberté, C., Khan, M., Okamoto, K., Chambers, J. W., Fletcher, P. J., et al. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-35 · Cited by 177
Hu, S., Begum, A. N., Jones, M. R., Oh, M. S., Beech, W. K., Beech, B. H., Yang, F., Chen, P., Ubeda, O. J., Kim, P. C., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.007 · Cited by 174
Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord
Hu, J. ‐., Zhang, H., Wagey, R., Krieger, C., & Pelech, S. L. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01670.x · Cited by 164
Watase, K., Gatchel, J. R., Sun, Y., Emamian, E., Atkinson, R., Richman, R., Mizusawa, H., Orr, H. T., Shaw, C., & Zoghbi, H. Y. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040182 · Cited by 163
A feasibility and tolerability study of lithium in Alzheimer's disease
Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 163
Echalier, A., Bettayeb, K., Ferandin, Y., Lozach, O., Clément, M., Valette, A., Liger, F., Marquet, B., Morris, J. C., Endicott, J. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm700940h · Cited by 162
Ribé, E. M., Pérez, M., Puig, B., Gich, I., Lim, F., Cuadrado, M., Sesma, T., Catena, S., Sánchez, B., Nieto, M., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.05.027 · Cited by 162
Silva, R., Mesquita, A. R., Bessa, J. M., Sousa, J. C., Sotiropoulos, I., Leão, P., Almeida, O. F. X., & Sousa, N. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.12.026 · Cited by 162
Lithium: Potential Therapeutics Against Acute Brain Injuries and Chronic Neurodegenerative Diseases
Wada, A., Yokoo, H., Yanagita, T., & Kobayashi, H. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj05009x · Cited by 161
Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100
Sun, X., Sato, S., Murayama, O., Murayama, M., Park, J.-M., Yamaguchi, H., & Takashima, A. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02583-6 · Cited by 161
Castelo‐Branco, G., Rawal, N., & Arenas, E. (2004) · Journal of Cell Science · doi:10.1242/jcs.01505 · Cited by 161
Antidepressant-like properties of zinc in rodent forced swim test
Kroczka, B., Branski, P., Palucha, A., Pilc, A., & Nowak, G. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00473-7 · Cited by 161
Ilouz, R., Kaidanovich, O., Gurwitz, D., & Eldar-Finkelman, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00636-8 · Cited by 160
Self-citationHongisto, V., Smeds, N., Brecht, S., Herdegen, T., Courtney, M. J., & Coffey, E. T. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6027-6036.2003 · Cited by 160
Zinc and depression. An update.
Nowak, G., Szewczyk, B., & Pilc, A. (2005) · PubMed · Cited by 158
Increase of BDNF Serum Concentration in Lithium Treated Patients with Early Alzheimer's Disease
Leyhe, T., Eschweiler, G. W., Stransky, E., Gasser, T., Annas, P., Basun, H., & Laske, C. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1004 · Cited by 158
Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity
Wang, W., Yang, Y., Ying, C., Li, W., Ruan, H., Zhu, X., You, Y., Han, Y., Chen, R., Wang, Y., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.03.017 · Cited by 158
Taşdemir, D., Mallon, R. G., Greenstein, M. D., Feldberg, L. R., Kim, S. C., Collins, K. C., Wojciechowicz, D. C., Mangalindan, G. C., Concepción, G. P., Harper, M. K., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102856 · Cited by 157
Li, T., Hawkes, C. A., Qureshi, H. Y., Kar, S., & Paudel, H. K. (2006) · Biochemistry · doi:10.1021/bi051635j · Cited by 156
Mettey, Y., Gompel, M., Thomas, V., Garnier, M., Leost, M., Ceballos-Picot, I., Noble, M. E. M., Endicott, J., VIERFOND, J. ‐., & Meijer, L. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020319p · Cited by 155
Hamann, M. T., Alonso, D. A., Martı́n-Aparicio, E., Fuertes, A., Perez-Puerto, M. J., Castro, A., Morales, S., Navarro, M. L., del Monte-Millán, M., Medina, M., et al. (2007) · Journal of Natural Products · doi:10.1021/np060092r · Cited by 154
Glycogen synthase kinase‐3β, or a link between amyloid and tau pathology?
Muyllaert, D., Kremer, A., Jaworski, T., Borghgraef, P., Devijver, H., Croes, S., Dewachter, I., & Leuven, F. V. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00376.x · Cited by 152
Insulin Mimetic Action of Synthetic Phosphorylated Peptide Inhibitors of Glycogen Synthase Kinase-3
Plotkin, B., Kaidanovich‐Beilin, O., Talior‐Volodarsky, I., & Eldar-Finkelman, H. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.047381 · Cited by 151
Self-citationSelenica, M. L., Jensen, H. S., Larsen, A. K., Pedersen, M. L., Helboe, L., Leist, M., & Lotharius, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707471 · Cited by 149
Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease
Hye, A., Kerr, F., Archer, N. J., Foy, C., Poppe, M., Brown, R. G., Hamilton, G., Powell, J. F., Anderton, B. H., & Lovestone, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.031 · Cited by 146
Rao, K. V., Donia, M. S., Peng, J., García‐Palomero, E., Alonso, D. A., Martínez, A., Medina, M., Franzblau, S. G., Tekwani, B. L., Khan, S. I., et al. (2006) · Journal of Natural Products · doi:10.1021/np0601399 · Cited by 144
Resolution of the Nuclear Localization Mechanism of Glycogen Synthase Kinase-3
Meares, G. P., & Jope, R. S. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700610200 · Cited by 142
Synthesis and Target Identification of Hymenialdisine Analogs
Wan, Y., Hur, W., Cho, C. Y., Liu, Y., Adrian, F. J., Lozach, O., Bach, S., Mayer, T., Fabbro, D., Meijer, L., et al. (2004) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.01.015 · Cited by 140
Evidence that glycogen synthase kinase‐3 isoforms have distinct substrate preference in the brain
Soutar, M. P. M., Kim, W.-Y., Williamson, R., Peggie, M. W., Hastie, C. J., McLauchlan, H., Snider, W. D., Gordon‐Weeks, P. R., & Sutherland, C. D. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06988.x · Cited by 139
Zinc deficiency induces depression-like symptoms in adult rats
Tassabehji, N. M., Corniola, R. S., Alshingiti, A., & Levenson, C. W. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.06.017 · Cited by 138
Isolation and X-ray crystal structure of a novel bromo-compound from two marine sponges
Cimino, G. G., de Rosa, S., Stefano, S. D., et al. (1982) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)86943-9 · Cited by 136
GSK-3 and the neurodevelopmental hypothesis of schizophrenia
Kozlovsky, N., Belmaker, R. H., & Agam, G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(01)00131-6 · Cited by 135
Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments
Gould, T. D., & Manji, H. K. (2006) · Wiley eBooks · doi:10.1002/0470052171.ch7 · Cited by 134
Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice
Rosa, A. O., Kaster, M. P., Binfaré, R. W., Morales, S., Martín-Aparicio, E., Navarro-Rico, M. L., Martínez, A., Medina, M., García, A. G., López, M. G., et al. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.05.020 · Cited by 132
Luna‐Medina, R., Cortés‐Canteli, M., Sánchez-Galiano, S., Morales-Garcia, J. A., Martínez, A., Santos, Á., & Pérez‐Castillo, A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1004-07.2007 · Cited by 127
Vougogiannopoulou, K., Ferandin, Y., Bettayeb, K., Myrianthopoulos, V., Lozach, O., Fan, Y., Johnson, C. H., Magiatis, P., Skaltsounis, A., Mikros, E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800648y · Cited by 124
Valerio, A., Bertolotti, P., Delbarba, A., Perego, C., Dossena, M., Ragni, M., Spano, P., Carruba, M. O., Simoni, M. G. D., & Nisoli, E. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07171.x · Cited by 124
Identification of the Axin and Frat Binding Region of Glycogen Synthase Kinase-3
Fraser, E., Young, N., Dajani, R. B., Franca‐Koh, J., Ryves, J., Williams, R. S. B., Yeo, M., Webster, M.-T., Richardson, C. D., Smalley, M. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109462200 · Cited by 121
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer’s disease
Forlenza, O. V., Torres, C. A., Talib, L. L., de Paula, V. D. J. R., Joaquim, H. P. G., Diniz, B. S., & Gattaz, W. F. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.06.002 · Cited by 119
Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3
Pérez, M., Rojo, A. I., Wandosell, F. G., Díaz‐Nido, J., & Ávila, J. (2003) · Biochemical Journal · doi:10.1042/bj20021596 · Cited by 118
Regulation of Glycogen Synthase Kinase 3β and Downstream Wnt Signaling by Axin
Hedgepeth, C. M., Deardorff, M. A., Rankin, K., & Klein, P. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.7147 · Cited by 118
Petit-Paitel, A., Brau, F., Cazareth, J., & Chabry, J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005491 · Cited by 117
Peineau, S., Nicolas, C. S., Bortolotto, Z. A., Bhat, R. V., Ryves, W. J., Harwood, A. J., Dournaud, P., Fitzjohn, S. M., & Collingridge, G. L. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-22 · Cited by 117
Shapira, M., Licht-Murava, A., Milman, A., Pick, C. G., Shohami, E., & Eldar-Finkelman, H. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.12.006 · Cited by 115
Self-citationRyves, W. J., Dajani, R. B., Pearl, L. H., & Harwood, A. J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6305 · Cited by 114
Kaidanovich‐Beilin, O., & Eldar-Finkelman, H. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090266 · Cited by 113
Self-citationGSK3β Regulates Myelin-Dependent Axon Outgrowth Inhibition through CRMP4
Alabed, Y. Z., Pool, M., Tone, S. O., Sutherland, C. D., & Fournier, A. E. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.6154-09.2010 · Cited by 112
Palomo, V., Soteras, I., Pérez, D. I., Pérez, C., Gil, C., Campillo, N. E., & Martínez, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200996g · Cited by 112
Busceti, C. L., Biagioni, F., Aronica, E., Riozzi, B., Storto, M., Battaglia, G., Giorgi, F. S., Gradini, R., Fornai, F., Caricasole, A., et al. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.01055.x · Cited by 109
Conde, S., Pérez, D. I., Martínez, A., Pérez, C., & Moreno, F. J. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034108b · Cited by 109
Kelly, S., Zhao, H., Sun, G. H., Cheng, D., Qiao, Y., Luo, J., Martin, K., Steinberg, G. K., Harrison, S. D., & Yenari, M. A. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.004 · Cited by 106
Making a neuron: Cdk5 in embryonic and adult neurogenesis
Jessberger, S., Gage, F. H., Eisch, A. J., & Lagace, D. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.07.002 · Cited by 105
Spittaels, K., den Haute, C. V., Dorpe, J. V., Terwel, D., Vandezande, K., Lasrado, R., Bruynseels, K., Irizarry, M. C., Verhoye, M., Lint, J. V., et al. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00236-1 · Cited by 104
Stukenbrock, H., Mußmann, R., Geese, M., Ferandin, Y., Lozach, O., Lemcke, T., Kegel, S., Lomow, A., Burk, U., Dohrmann, C. E., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701582f · Cited by 101
Caspi, M., Zilberberg, A., Eldar-Finkelman, H., & Rosin‐Arbesfeld, R. (2008) · Oncogene · doi:10.1038/sj.onc.1211026 · Cited by 101
Self-citationGenetic and pharmacological evidence for schizophrenia‐related Disc1 interaction with GSK‐3
Lipina, T. V., Kaidanovich‐Beilin, O., Patel, S., Wang, M., Clapcote, S. J., Liu, F., Woodgett, J. R., & Roder, J. (2010) · Synapse · doi:10.1002/syn.20839 · Cited by 100
Chioua, M., Samadi, A., Soriano, E., Lozach, O., Meijer, L., & Marco, J. L. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.06.099 · Cited by 98
The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease
Hernández, F., & Ávila, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.026 · Cited by 98
Lithium and dementia: A preliminary study
Terao, T., Nakano, H., Inoue, Y., Okamoto, T., Nakamura, J., & Iwata, N. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.04.020 · Cited by 98
Peng, J., Kudrimoti, S., Sivaprakasam, P., Odde, S., Doerksen, R. J., Pennaka, H. K., Choo, Y., Rao, K. V., Tekwani, B. L., Madgula, V. L. M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900672t · Cited by 96
Does Lithium Therapy Protect Against the Onset of Dementia?
Dunn, N., Holmes, C., & Mullee, M. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000155068.23937.9b · Cited by 94
Koh, S., Kim, Y., Kim, H. Y., Hwang, S., Lee, C. H., & Kim, S. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.03.004 · Cited by 91
Mishra, R., Barthwal, M. K., Sondarva, G. V., Rana, B., Wong, L., Chatterjee, M., Woodgett, J. R., & Rana, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705895200 · Cited by 90
Culbert, A. A., Brown, M. J. B., Frame, S., Hagen, T., Cross, D. A. E., Bax, B. D., & Reith, A. D. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02990-8 · Cited by 89
Takahashi, M., Yasutake, K., & Tomizawa, K. (1999) · PubMed · Cited by 88
A screen for regulators of survival of motor neuron protein levels
Makhortova, N. R., Hayhurst, M., Cerqueira, A., Sinor, A. D., Zhao, W., Heiser, P. W., Arvanites, A. C., Davidow, L. S., Waldon, Z., Steen, J. A. J., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.595 · Cited by 87
The Current Status of Drug Discovery Against the Human Kinome
Eglen, R. M., & Reisine, T. (2009) · Assay and Drug Development Technologies · doi:10.1089/adt.2008.164 · Cited by 85
Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins
Akué‐Gédu, R., Débiton, E., Ferandin, Y., Meijer, L., Prudhomme, M., Anizon, F., & Moreau, P. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.017 · Cited by 85
Wood, N. I., & Morton, A. J. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00141-2 · Cited by 84
Burstein, D. E., Seeley, P. J., & Greene, L. A. (1985) · The Journal of Cell Biology · doi:10.1083/jcb.101.3.862 · Cited by 84
Kuo, G., Prouty, C. P., DeAngelis, A., Shen, L., O’Neill, D. J., Shah, C. R., Connolly, P. J., Murray, W. V., Conway, B. R., Cheung, P., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030115o · Cited by 83
Peptide Inhibitors Targeting Protein Kinases
Eldar-Finkelman, H., & Eisenstein, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788682253 · Cited by 82
Self-citationLithium Increases Synapse Formation between Hippocampal Neurons by Depleting Phosphoinositides
Kim, H. J., & Thayer, S. A. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.052357 · Cited by 81
Pérez, D. I., Palomo, V., Pérez, C., Gil, C., Dans, P. D., Luque, F. J., Conde, S., & Martínez, A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1016279 · Cited by 80
Ding, Y., Qiao, A., & Fan, G.-H. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.022 · Cited by 76
Martin, L., Magnaudeix, A., Esclaire, F., Yardin, C., & Terro, F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.11.057 · Cited by 76
Ghribi, O., Herman, M. M., & Savory, J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10511 · Cited by 74
Jin, N. Y., Kovács, A., Sui, Z., Dewhurst, S., & Maggirwar, S. B. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.010 · Cited by 73
A molecular cell biology of lithium
Williams, R. S. B., Ryves, W. J., Dalton, E. C., Eickholt, B. J., Shaltiel, G., Agam, G., & Harwood, A. J. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320799 · Cited by 71
Rao, R., Hao, C., Redha, R., Wasserman, D. H., McGuinness, O. P., & Breyer, M. D. (2006) · Diabetologia · doi:10.1007/s00125-006-0552-5 · Cited by 70
Kalinichev, M., & Dawson, L. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001495 · Cited by 70
Kirshenboim, N., Plotkin, B., Shlomo, S. B., Kaidanovich‐Beilin, O., & Eldar-Finkelman, H. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:2:237 · Cited by 68
Self-citationPotent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine
Sharma, V., & Tepe, J. J. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.05.079 · Cited by 67
Bone, H. K., Damiano, T., Bartlett, S. T., Perry, A., Letchford, J., Sanchez-Ripoll, Y., Nelson, A. S., & Welham, M. J. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.11.003 · Cited by 66
Glycogen Synthase Kinase-3β Inhibition Reduces Secondary Damage in Experimental Spinal Cord Trauma
Cuzzocrea, S., Genovese, T., Mazzon, E., Crisafulli, C., Paola, R. D., Muià, C., Collin, M., Esposito, E., Bramanti, P., & Thiemermann, C. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102863 · Cited by 66
Hu, J., Hamann, M. T., Hill, R. T., & Kelly, M. (2003) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/s0099-9598(03)60004-0 · Cited by 66
Frank, G. (1993) · Psychological Reports · doi:10.2466/pr0.1993.72.3c.1184 · Cited by 64
Ilouz, R., Kowalsman, N., Eisenstein, M., & Eldar-Finkelman, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604633200 · Cited by 62
Self-citationBrewster, J. L., Linseman, D. A., Bouchard, R. J., Loucks, F. A., Precht, T. A., Esch, E. A., & Heidenreich, K. A. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2006.04.006 · Cited by 62
Takadera, T., & Ohyashiki, T. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.07.115 · Cited by 61
Alon, L. T., Pietrokovski, S., Barkan, S., Avrahami, L., Kaidanovich‐Beilin, O., Woodgett, J. R., Barnea, A., & Eldar-Finkelman, H. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.025 · Cited by 60
Self-citationChuang, D., & Manji, H. K. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.04.008 · Cited by 60
Azoulay‐Alfaguter, I., Yaffe, Y., Licht-Murava, A., Urbańska, M., Jaworski, J., Pietrokovski, S., Hirschberg, K., & Eldar-Finkelman, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.127969 · Cited by 59
Self-citationSaus, E., Soria, V., Escaramís, G., Crespo, J. M., Valero, J., Gutiérrez‐Zotes, A., Martorell, L., Vilella, E., Menchón, J. M., Estivill, X., et al. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00617.x · Cited by 58
Pérez, D. I., Conde, S., Pérez, C., Gil, C., Simón, D., Wandosell, F. G., Moreno, F. J., Gelpí, J. L., Luque, F. J., & Martínez, A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.08.042 · Cited by 58
Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 55
Targeting insulin-like growth factor-1 to treat Alzheimer's disease
Torres‐Alemán, I. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.12.1535 · Cited by 53
Cheng, K., Creacy, S. D., & Larner, J. (1983) · Molecular and Cellular Biochemistry · doi:10.1007/bf00227219 · Cited by 49
Glycogen synthase kinase-3 inhibitors protect central neurons against excitotoxicity
Facci, L., Stevens, D. A., & Skaper, S. D. (2003) · Neuroreport · doi:10.1097/00001756-200308060-00012 · Cited by 48
Oral Administration of a GSK3 Inhibitor Increases Brain Insulin-like Growth Factor I Levels
Bolós, M., Fernández, S., & Torres‐Alemán, I. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096594 · Cited by 44
Glycogen synthase kinase-3β in the platelets of patients with mood disorders: Effect of treatment
Pandey, G. N., Ren, X., Rizavi, H. S., & Dwivedi, Y. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.07.009 · Cited by 44
Isomers and Tautomers of Hymenialdisine and Debromohymenialdisine
Williams, D. H., & Faulkner, D. J. (1996) · Natural product letters · doi:10.1080/10575639608043579 · Cited by 42
Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-Dependent kinases inhibitors
Ortega, M. A., Romero-Montoya, M. E., Zarranz, B., Jaso, A., Aldana, I., Leclerc, S., Meijer, L., & Monge, A. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00069-x · Cited by 41
Crouch, P. J., Cole, A. R., Cousin, M. A., Martı́nez, A., & Kanninen, K. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/279234 · Cited by 39
Sodium tungstate decreases the phosphorylation of tau through GSK3 inactivation
Gómez‐Ramos, A., Domínguez, J. E., Zafra, D., Corominola, H., Gomis, R., Guinovart, J. J., & Ávila, J. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20726 · Cited by 38
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Xin, H., Katakowski, M., Wang, F., Qian, J.-Y., Liu, X. S., Ali, M. M., Buller, B., Zhang, Z. G., & Chopp, M. (2017) · Stroke · doi:10.1161/strokeaha.116.015204 · Cited by 533
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
GSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“Several GSK-3 inhibitors have been shown to reduce tau phosphorylation in cells and in preclinical studies in mice (reviewed in [188]).”
BackgroundWu, Z.-Q., Li, X.-Y., Hu, C. Y., Ford, M., Kleer, C. G., & Weiss, S. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205822109 · Cited by 305
Metadata
- Authors
- Eldar-Finkelman, H., & Martinez, A.
- Venue
- Frontiers in Molecular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2011
- Volume
- 4
- Pages
- 32-32
- ISSN
- 1662-5099 (ISSN-L)
- OpenAlex
- W1975257189
- Cited by
- 354
- References
- 217
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.